James Li

Director at AirNexis Therapeutics

Capital raised by AirNexis Therapeutics

$62.0M+$62.0M latest round

1 Form D filing · first filed Jan 2026 · Palo Alto, CA

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: 2024
30D INTEREST: 2 ↗

Career

1 company on file · founded 2024

AirNexis TherapeuticsBiotech · Palo Alto, CAsince 2024

Director

Listed on AirNexis Therapeutics's Form D filings

Company filings

via EDGAR · Form D for AirNexis Therapeutics1

DateCompanyFormAmountRole on filing

Jan 9, 2026AirNexis TherapeuticsForm D+$62.0M—

Form DJan 9, 2026 · AirNexis Therapeutics+$62.0Mnot a signer

Overview

Last filing Jan 9, 2026

James Li is on file as Director at AirNexis Therapeutics in Palo Alto, CA. AirNexis Therapeutics has 1 Form D filing on record, $62.0M raised in total.

Teammates

AirNexis Therapeutics · 1

Maria FardisChief Executive OfficerSigner

Products

AirNexis Therapeutics · 1

AN01 (HSK39004)COPD Therapeutic

AN01 is an inhaled, dual-mechanism phosphodiesterase 3 and 4 (PDE3/4) inhibitor in Phase 2 development. It is intended for the maintenance treatment of COPD. The company holds exclusive global development rights outside of Greater China, having licensed the asset from Haisco Pharmaceutical Group, which previously advanced it through Phase 2 trials in China.